Individualized dosing with axitinib: rationale and practical guidance.

Abstract

Axitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have demonstrated high interpatient variability in patients receiving the 5 mg twice-daily (b.i.d.) starting dose. Clinical criteria can be used to assess whether individual patients may benefit further from dose modifications, based on their safety and tolerability data. This review provides practical guidance on the 'flexible dosing' method, to help physicians identify who would benefit from dose escalations, dose reductions or continuation with manageable toxicity at the 5 mg b.i.d. dose. This flexible approach allows patients to achieve the best possible outcomes without compromising safety.

• Authors: Manuela Schmidinger, Romano Danesi, Robert Jones, Ray McDermott, Lynda Pyle, Brian Rini, Sylvie Négrier
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 9 Pg. 861-875 (Apr 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29264944 (Publication Type: Journal Article, Review)

Chemical References

• Imidazoles
• Indazoles
• Protein Kinase Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Axitinib

Topics

• Axitinib
• Carcinoma, Renal Cell (drug therapy, genetics, pathology)
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Indazoles (adverse effects, therapeutic use)
• Kaplan-Meier Estimate
• Molecular Targeted Therapy
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors, genetics)